Join the club for FREE to access the whole archive and other member benefits.

Placental stem cell derived NK cells are effective against multiple myeloma

Preliminary results from Phase 1 trial look promising

08-Jan-2020

Key points from article :

An investigational cell therapy is safe and leads to good response rates against multiple myeloma.

PNK-007 is a therapy derived from placental stem cells.

Placenta-derived blood stem cells are differentiated into natural killer (NK) cells.

Induce cancer cell death and recruit other immune cells into the tumour environment.

Well-tolerated and no reports of serious adverse events or dose-limiting toxicity up to now.

15 participants, from 44 to 69 years old took part in this clinical trial.

Clinical trial by Celularity presented at American Society of Haematology.

Mentioned in this article:

Click on resource name for more details.

Celularity

Cell therapeutics company

Robert J. Hariri

Surgeon, biomedical scientist and serial entrepreneur in biomedicine and aerospace

Topics mentioned on this page:
Stem Cells, Cancer